Vir Biotechnology Inc. and GlaxoSmithKline plc said Monday that they have commenced dosing of patients with VIR-7831 in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment.
The study will enroll about 1,300 patients worldwide who have early symptomatic infection. It will assess whether VIR-7831, as a single-dose monoclonal antibody, could prevent hospitalization due to the COVID-19.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com